Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Moderate to Severe Mitral Stenosis: A Systematic Review

Article Cardiac & Cardiovascular Systems

RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial

Parham Sadeghipour et al.

Summary: In patients with atrial fibrillation and moderate-to-severe mitral stenosis, rivaroxaban shows acceptable efficacy and safety, suggesting the need for larger randomized controlled trials in this population.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Atrial valvular fibrillation: OAC or VKA?

H. Vaillant et al.

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Add to Collection

Article Medicine, General & Internal

Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation

S. J. Connolly et al.

Summary: Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy leads to a lower rate of a composite of cardiovascular events or death compared to rivaroxaban therapy, without a higher rate of bleeding.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Gerhard Hindricks et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Endocrinology & Metabolism

Orthostatic intolerance after bariatric surgery: A systematic review and meta-analysis

Jawahar Al Nou'mani et al.

Summary: This study aimed to summarize evidence of orthostatic intolerance after bariatric surgery and found a 5-year cumulative incidence rate of 4.2% with common clinical presentations of lightheadedness, dizziness, syncope, and palpitation. Pooled data suggested improvement in overall cardiac autonomic function post-surgery.

CLINICAL OBESITY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Catherine M. Otto et al.

Summary: Supplemental digital content is available in the text.

CIRCULATION (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation A Population-Based Cohort Study

Ghadeer K. Dawwas et al.

Summary: In a retrospective cohort study, new users of direct oral anticoagulants (DOACs) in patients with valvular atrial fibrillation (AF) had lower risks of ischemic stroke or systemic embolism, as well as major bleeding, compared to new users of warfarin. constsistent results were found for apixaban and rivaroxaban, but not dabigatran in terms of effectiveness and safety outcomes.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal